Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab

World News: . []

CRESTWOOD Ky and WALTHAM Mass April 16 2018 GLOBE NEWSWIRE) -- NasdaqAPLS a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of autoimmune and inflammatory diseases today a...

More news and information about Apellis Pharmaceuticals, Inc.

Published By:

Globe Newswire: 14:23 GMT Monday 16th April 2018

Published: .

Search for other references to "apellis" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us